CCF Highlights

At the 2022 annual meeting of the Cholangiocarcinoma (CCA) Foundation, a case-based panel discussion focused on multidisciplinary care of CCA.

Rachna T. Shroff, MD, MS, Chief, Section of Gastrointestinal Medical Oncology, University of Arizona Cancer Center, Tucson, reviewed promising clinical data regarding novel targeted therapies currently under clinical investigation for the treatment of cholangiocarcinoma.

At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Dr Shahid Khan, Clinical Senior Lecturer at Imperial College London, discussed the need for correct International Classification of Diseases coding for CCA.

One session at the 2022 Cholangiocarcinoma Foundation annual meeting focused on the role of microbiome in the pathogenesis of hepatobiliary cancers.

At the 2022 Cholangiocarcinoma (CCA) Foundation annual meeting, Ambuj Srivastava shared his experience as a current caregiver for his dad who was diagnosed with stage 2 extrahepatic CCA.

At the 2022 CCF annual meeting, 2 patients very eloquently described their respective journeys with cholangiocarcinoma (CCA) and shared their perspectives on how to best manage the disease.

On the second day of the 2022 Cholangiocarcinoma Foundation annual meeting, Lipika Goyal, MD, MPhil, Assistant Professor of Medicine, Harvard Medical School, and Lead, Liver Cancer Research Program, Massachusetts General Hospital Cancer Center, Boston, presented a clinical update on emerging systemic therapies in cholangiocarcinoma (CCA).

The International Cholangiocarcinoma Research Network (ICRN) is a program initiated by the Cholangiocarcinoma Foundation (CCF). The core mission of this network of international experts is “to rapidly translate scientific discoveries into practice for cholangiocarcinoma patients through a collaborative, highly translational international research network.”

At the 2020 virtual conference of the Cholangiocarcinoma Foundation (CCF), William W. Li, MD, Chief Executive Officer, President, and Medical Director of the Angiogenesis Foundation in Cambridge, MA, presented the keynote address titled “Dietary Modification of the Tumor Microenvironment: New Frontiers in Cancer Research and Therapy.”

At the 2020 virtual conference of the Cholangiocarcinoma Foundation (CCF), results of a patient survey conducted in summer 2019 by the CCF and Incyte Corporation, provided real-life responses from patients regarding the impact of a cholangiocarcinoma (CCA) diagnosis on patients with this rare disease.